Upon completion of this continuing education activity, learners will be able to demonstrate mastery of the following competencies across knowledge-based and application-based domains. These objectives are designed to prepare pharmacists and allied healthcare providers for immediate clinical application in outpatient, ambulatory, and community pharmacy settings.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM). Over the past decade, this class has rapidly evolved from a "diabetes drug" into a multi-system metabolic therapy platform — with established or emerging indications spanning obesity, atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), heart failure with preserved ejection fraction (HFpEF), peripheral artery disease (PAD), and most recently obstructive sleep apnea (OSA).

The commercial trajectory mirrors the clinical one: the global GLP-1 market is projected to reach approximately $200 billion by 2031, with more than 30 agents in development across oral, weekly, and dual/triple-receptor formulations. The April 2026 FDA approval of Foundayo (orforglipron) — the first oral, non-peptide, small-molecule GLP-1 receptor agonist — represents a meaningful expansion of access, lowering the practical and psychological barriers (injections, cold-chain storage, fasting requirements) that have limited uptake in populations who are otherwise excellent candidates for this therapy.

The clinical expansion of the GLP-1 class has been remarkably rapid, progressing from a single indication to a multi-organ disease-modifying platform within two decades.

Eight GLP-1 RA molecules are now commercially available in the United States across oral and subcutaneous routes, with daily, twice-daily, and weekly dosing schedules. Tirzepatide, marketed as Mounjaro for T2DM and Zepbound for chronic weight management and OSA, remains the only currently available dual GLP-1/GIP receptor agonist. Orforglipron, approved by the FDA on April 1, 2026 and marketed as Foundayo, is the first oral non-peptide small-molecule GLP-1 receptor agonist and is approved exclusively for chronic weight management.

ATTAIN-1 was a 72-week, randomized, double-blind, placebo-controlled Phase 3 trial in adults with obesity or overweight with ≥1 weight-related comorbidity. The 36 mg orforglipron capsule used in trials is dose-equivalent to the 17.2 mg FDA-approved tablet strength.

Each dose step requires a minimum of 30 days before advancing. The maintenance dose is selected based on individual treatment response and tolerability. Do not exceed one tablet per day. Do not co-administer with any other GLP-1 receptor agonist — this is an explicit labeled warning for Foundayo.

The 2025 American Diabetes Association (ADA) Standards of Care position GLP-1 RAs as preferred agents — independent of metformin and independent of baseline A1c — in patients with established ASCVD, high cardiovascular risk, CKD, heart failure, or who would benefit from weight management. The default first-line regimen for patients without these compelling indications remains metformin plus comprehensive lifestyle intervention.

Across the class, GLP-1 RAs lower A1c by approximately 0.5%–2.5%, with tirzepatide demonstrating the greatest reductions observed in the class and exenatide demonstrating the most modest effects. Understanding this potency hierarchy is essential for agent selection when glycemic control is the primary driver of therapy decisions.

GLP-1 RAs produce clinically meaningful, sustained weight reduction that surpasses older anti-obesity agents (phentermine, naltrexone-bupropion, orlistat) and is superior to most non-GLP-1 prescription options. The magnitude of weight loss varies substantially between agents and between the diabetes and non-diabetes populations — a distinction with real clinical relevance for agent selection and patient counseling.

The 2025 ADA Standards of Care recommend a GLP-1 RA with proven cardiovascular benefit as first-line in adults with T2DM and either established ASCVD or high cardiovascular risk (age ≥55 with ≥2 of: hypertension, dyslipidemia, smoking, obesity). The SELECT trial in 2023 fundamentally expanded this principle: GLP-1 RAs are now cardiovascular drugs, not just diabetes medications. Subcutaneous semaglutide (Wegovy) is now FDA-approved for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease — even in the absence of diabetes.

Both drug classes offer cardiorenal protection, but through distinct mechanisms. The real-world decision is rarely either/or — combination therapy is now supported by both ADA and KDIGO guidelines when tolerability, cost, and access permit.

Heart failure with preserved ejection fraction has historically been a difficult-to-treat phenotype, with limited disease-modifying options outside of SGLT2 inhibitors. Two pivotal trials have now brought GLP-1 / GIP-GLP-1 RAs into the HFpEF conversation, reshaping how pharmacists should counsel patients with this challenging diagnosis.

Comprehensive monitoring throughout GLP-1 RA therapy is not optional and it is not merely routine follow-up. It is the clinical infrastructure that makes treatment safe, effective, and sustainable over time. These agents influence multiple organ systems at once — including the pancreas, kidneys, cardiovascular system, gastrointestinal tract, thyroid, gallbladder, and retina — so monitoring must be broader than what is required for most single-indication drug classes.

For the pharmacist, monitoring is not confined to the dispensing counter. It includes proactive symptom screening at every refill, recognition of red-flag findings that require urgent referral, and coordination with prescribers when laboratory values or clinical changes suggest the need for dose adjustment, closer follow-up, or discontinuation. In practice, monitoring is how GLP-1 RA therapy stays aligned with the patient rather than the prescription label.

Before discussing specific labs and symptoms, it helps to define the framework behind GLP-1 RA monitoring. First, baseline monitoring and ongoing monitoring serve different purposes. Baseline labs and clinical assessment establish the starting point, identify contraindications or pre-existing risk factors, and give the care team something to compare against later. Ongoing monitoring then tracks response, detects emerging adverse effects, and informs whether titration should continue, pause, or stop.

Second, many commonly monitored values are surrogate endpoints rather than clinical outcomes. A1c and eGFR are not the outcome themselves; they are markers that predict downstream outcomes such as cardiovascular events, kidney failure, and long-term microvascular harm. Monitoring them allows clinicians to intervene early, before irreversible damage occurs. That is why these numbers are so valuable even when the patient is not yet reporting symptoms.

Third, monitoring intervals are not arbitrary. They reflect the natural history of the conditions being treated and the known timeline of adverse effects associated with the drug class. The follow-up schedule should become more frequent during initiation and titration, then stabilize once the patient is at a maintenance dose and clinically stable.

Finally, the pharmacist’s role depends on the practice setting. In community pharmacy, monitoring is usually symptom-based and refill-based: asking the right questions, noticing warning signs, and escalating concerns. In ambulatory care or collaborative practice settings, pharmacists may also order, interpret, and trend laboratory values directly.

A1c every 3 months until target: A1c reflects average blood glucose over roughly 3 months, which corresponds to the lifespan of red blood cells. Monitoring every 3 months during titration gives the clinician enough time to see whether the medication is working, whether dose escalation is needed, and whether glycemic improvement is too rapid in a patient also using insulin or a sulfonylurea. Once the patient is stable and at goal, every 6 months is usually sufficient.

eGFR and UACR: eGFR estimates kidney filtration capacity, while UACR detects early kidney injury by measuring albumin leakage into the urine. Together, they provide a practical view of renal health. This matters especially because GLP-1 RAs have demonstrated nephroprotective effects in outcomes trials, including FLOW with semaglutide, making baseline and ongoing renal monitoring important both to document benefit and to detect any unexpected decline. In patients with chronic kidney disease, more frequent monitoring every 3 to 6 months is reasonable.

Hypoglycemia risk: GLP-1 RAs alone have very low intrinsic hypoglycemia risk because their insulin-stimulating effect is glucose-dependent — they work primarily when glucose is elevated. That changes when they are combined with insulin or sulfonylureas, where additive glucose lowering can cause hypoglycemia. Patients on combination therapy should be taught how to recognize and treat low blood sugar, and insulin or sulfonylurea doses may need to be reduced when a GLP-1 RA is added.

Body weight and BMI: Weight trajectory is a primary efficacy endpoint in obesity treatment and an important secondary endpoint in type 2 diabetes. Recording weight at every encounter creates a longitudinal trend that helps show response, supports prior authorization renewals, and identifies non-responders early — often defined as less than 5% weight loss at 12 to 16 weeks. Patients benefit from seeing the data too; someone who has lost 8% of body weight in 4 months should be able to recognize that success clearly.

Blood pressure and heart rate: GLP-1 RAs usually produce modest reductions in systolic blood pressure, typically in the range of about 2 to 5 mmHg, likely through weight loss and natriuresis. They can also cause a small increase in resting heart rate, often about 2 to 4 bpm. That rise is usually clinically insignificant, but it matters in patients with pre-existing tachyarrhythmias or symptomatic palpitations. Measuring both at each visit creates a more complete cardiovascular picture.

Lipid panel: These agents can improve the lipid profile modestly, especially triglycerides and non-HDL cholesterol, with small LDL reductions in some patients. These improvements are secondary to better glycemic control and weight loss rather than a direct lipid-lowering mechanism. Periodic monitoring — generally annually or based on cardiovascular risk — is appropriate.

GI symptom monitoring: Nausea, vomiting, diarrhea, constipation, and early satiety are the most common adverse effects in the class and a leading reason for discontinuation. Asking about these symptoms at every refill is not a courtesy question — it is an intervention. It gives the pharmacist a chance to recommend dose holds, dietary adjustments, hydration strategies, or antiemetic support before the patient decides on their own that the medication is intolerable.

Pancreatitis: GLP-1 RAs carry a labeled warning for acute pancreatitis. The mechanism is not fully established, and the causal signal remains debated in the literature, but the warning is clinically important. The classic red-flag presentation is severe, persistent mid-epigastric or upper abdominal pain that may radiate to the back. This requires immediate discontinuation of the drug and urgent medical evaluation. Patients should be told explicitly to stop the medication and seek care right away if this occurs.

Gallbladder disease: Rapid weight loss of any cause raises the risk of gallstones and cholecystitis, and GLP-1 RAs can contribute through both weight loss and possible direct effects on gallbladder motility. Right upper quadrant pain, jaundice, fever, and nausea after fatty meals are important warning signs. Patients with a history of gallstones should be monitored especially carefully.

Foundayo-specific monitoring: Orforglipron (Foundayo) has FDA postmarketing requirements for hair loss and liver enzyme monitoring. Alopecia can occur with rapid weight loss across the class, but it was specifically flagged in Foundayo trials. Liver enzyme elevations were seen in a small subset of patients, so periodic ALT and AST monitoring is appropriate per prescribing information. Pharmacists should ask about hair loss and unusual fatigue, which can be a clue to hepatic injury.

Thyroid symptoms: Most GLP-1 RAs, except exenatide IR, carry a boxed warning for thyroid C-cell tumors based on rodent data. The human risk is considered low and unproven, but counseling remains important. Patients should report neck mass, hoarseness, difficulty swallowing, or persistent shortness of breath because those symptoms may reflect thyroid pathology that warrants prompt evaluation. This is not a reason to avoid the drug in most patients, but it is a reason to monitor carefully.

Diabetic retinopathy: Rapid A1c reduction — especially a drop of more than 2% within the first 3 to 6 months — has been associated with transient worsening of diabetic retinopathy, a phenomenon known as early worsening. This is well documented with insulin intensification and has also been observed with semaglutide in SUSTAIN-6. Patients with pre-existing moderate to severe retinopathy should have ophthalmology follow-up before and during rapid improvement. This does not mean GLP-1 RAs should be avoided in those patients; the long-term benefit usually outweighs the short-term risk, but monitoring is essential.

Injection site assessment: For subcutaneous formulations, inspect injection sites for lipohypertrophy, which can appear as fatty lumps from repeated injections in the same area. Lipohypertrophy can impair absorption and reduce efficacy. Patients should be taught to rotate sites systematically among the abdomen, thigh, and upper arm and to avoid injecting into areas of visible or palpable lipohypertrophy.

Monitoring works best when it is built into routine refill interactions rather than treated as a separate task. At every refill, pharmacists should use a simple structured script and adapt it to the patient's indication, comorbidities, and therapy intensity. The goal is to identify problems early enough to preserve adherence and prevent avoidable harm.

At every refill, ask four key questions: 1) How is your stomach tolerating it? 2) Have you noticed any unusual symptoms — neck swelling, severe abdominal pain, or right-sided pain after eating? 3) Are you checking your blood sugar regularly if you are also on insulin or a sulfonylurea? 4) Have you had any recent labs?

Flag and act: If a patient reports severe abdominal pain, hold the medication and refer urgently. If a patient reports neck swelling or hoarseness, contact the prescriber promptly. If a patient on insulin reports frequent hypoglycemia, the prescriber may need to reduce the insulin dose. If recent labs show a renal decline, unexplained liver enzyme elevation, or rapid A1c drop with retinopathy risk, escalate the concern rather than waiting for the next refill.

Document: Every monitoring conversation should be documented in the dispensing system or patient record. Documentation protects the pharmacist, supports continuity of care, and creates a longitudinal record that helps the entire care team see what was asked, what was found, and what action was taken.

Effective patient counseling is the most consistent predictor of adherence and long-term persistence with GLP-1 RA therapy. Community and ambulatory care pharmacists are uniquely positioned to deliver the comprehensive medication education that drives real-world outcomes — particularly as this class expands to cover complex multi-system indications and multiple oral and injectable formulations simultaneously on the market. Counseling should be individualized by route, indication, and patient-specific adherence barriers.

The following evidence-based counseling scripts are field-tested for community pharmacy application. Adapt language to the patient's health literacy level while preserving the core clinical messages.

Beyond evidence and guidelines, pharmacists are the front line for the operational challenges that determine whether GLP-1 therapy actually works for a given patient. This section addresses the "how patients get hurt in real life" scenarios — drug shortages, missed doses, self-pay access, switching dilemmas, microdosing risks, compounded products, and the practical integration of Foundayo into a rapidly evolving formulary landscape. These are not academic exercises; they are the daily realities of GLP-1 dispensing in 2026.

The following six multiple-choice questions assess mastery of the core learning objectives. Read each question and all distractors carefully before selecting your answer. Answers and detailed rationale appear in the following section. Each rationale references the corresponding citation from Section 18.